Slide 1: Financial Results Analysis
Financial Results Analysis Quarter & 9 Months Ended December 31, 2011
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Quarterly Results Analysis
Quarterly Results Analysis 22
Slide 4: Financial Highlights – Q3'FY12
Financial Highlights – Q3’FY12 • Net Sales at Rs. 1,087crs for Q3’FY12, grew 25% YoY • Record highest ever sales in a quarter • Revenue from Products Business at Rs. 867crs, grew 24% • Revenue from Services Business at Rs. 220crs, grew 32% • EBITDA at Rs. 212crs in Q3’FY12, up 58% YoY • Margins at 1
Slide 5: Income Statement – Q3'FY12
Income Statement – Q3’FY12 Particulars Q3'FY11 Q3'FY12 YoY Growth (Rs Crs) (%) Net Sales 866 1,087 25% Other operating Income 3 1 Income from Operations 869 1,088 25% Total Expenditure 737 880 19% Operating Profit 132 208 58% Other Income 2 4 EBITDA including Other Income 134 212 58% Depreciation 49
Slide 6: Revenue Analysis – Business wise – Q3'FY12
Revenue Analysis – Business wise – Q3’FY 12 Q3'FY11 Q3'FY12 Revenue YoY (Rs crs) Mix (%) Growth % Life Science Ingredients (LSI) 582 656 60% 13% Generics (GX) 118 211 19% 78% Life Science Products 700 867 80% 24% CMO 115 157 14% 37% DDDS 49 59 5% 22% Others 3 4 0% 25% Life Science Services 167 220 2
Slide 7: Highlights – Life Science Products – Q3'FY12
Highlights – Life Science Products- Q3’FY12 Life Science Products Revenue at Rs. 867crs, grew 24% YoY • Growth driven by volume and positive price variance of 16.3% • Positive foreign exchange fluctuation impact of 7.7% 1. Life Science Ingredients – Rs. 656crs, 60% of Revenue Mix • Constitutes APIs,
Slide 8: Highlights – Life Science Services – Q3'FY12
Highlights – Life Science Services- Q3’FY12 Life Science Services Business Revenues at Rs. 220crs, grew 32% YoY • Constitutes the CMO, DDDS and Healthcare business 1. CMO Services of Sterile Injectables and Non-sterile products at Rs. 157crs • Grew 37%, contributed over 14% to revenue mix • Strategi
Slide 9: Revenue Analysis – Geography wise – Q3'FY12
Revenue Analysis – Geography wise- Q3’FY12 Emerg. Mkts China 6% (Rs crs) Q3' FY11 Q3' FY12 Mix % YoY % 7% India India 267 320 29% 20% 29% International 599 767 71% 28% Europe & Japan USA & Canada 308 428 39% 39% 19% Europe & Japan 136 207 19% 52% China 94 71 6% -25% USA & Emerging Markets 62 61 6% 0
Slide 10: Operating Expenditure Analysis – Q3'FY12
Operating Expenditure Analysis – Q3’FY12 Expenses YoY Q3’FY11 % of Sales Q3’FY12 % of Sales (Rs Crs) Growth % Material 408 47% 453 42% 11% Manufacturing 70 8% 103 9% 47% Staff 178 21% 228 21% 28% SG&A 81 9% 95 9% 18% • Share of Material Costs to sales down to 42% due to • Higher value addition in ve
Slide 11: EBITDA Analysis Q3'FY12
EBITDA Analysis Q3’FY12 EBITDA (Rs. Crs) Q3’FY11 Q3’FY12 YoY Growth % Products Business 160 204 28% Services Business (3) 24 866% Reported EBITDA 134 212 58% Margins (%) Q3’FY11 Q3’FY12 bps variance Products Business 22.8% 23.6% 77 Services Business -1.9% 10.9% 1,277 Consolidated 15.4% 19.5% 405 Rep
Slide 12: 9 Months Results Analysis
9 Months Results Analysis 11 11
Slide 13: Financial Highlights – 9M'FY12
Financial Highlights – 9M’FY12 • Revenue of Rs. 3,080crs for 9M’FY12, grew 21% YoY • Highest ever sales in Nine Month period • Revenue from Products Business at Rs. 2,439crs, grew 23% • Revenue from Services Business at Rs. 640crs, grew 15% • EBITDA at Rs. 643crs in 9M’FY12, up 50% YoY • Margins at
Slide 14: Income Statement – 9M'FY12
Income Statement – 9M’FY12 Particulars 9M'FY 11 9M'FY 12 YoY Growth (Rs Crs) (%) Net Sales 2543 3080 21% Other operating Income 5 7 Income from Operations 2548 3087 21% Total Expenditure 2126 2454 15% Operating Profit 422 632 50% Other Income 8 11 EBITDA including Other Income 430 643 50% Depreciati
Slide 15: Revenue Analysis – Business wise – 9M'FY12
Revenue Analysis – Business wise – 9M’FY12 9M'FY 11 9M'FY 12 Revenue Mix (%) YoY Growth % Business wise Revenue Rs. Crore Life Science Ingredients (LSI) 1,660 1,856 60% 12% Generics (GX) 327 583 19% 78% Life Science Products 1,987 2,439 79% 23% CMO 393 462 15% 18% DDDS 154 169 5% 9% Others 9 10 0% 8
Slide 16: Highlights – Life Science Products – 9M'FY12
Highlights – Life Science Products- 9M’FY 12 Life Science Products Revenue at Rs. 2,439crs in 9M’FY12, grew 23%YoY • Growth driven by volume and positive price variance of 21% • Positive foreign exchange fluctuation impact of 2% 1. Life Science Ingredients revenue of Rs. 1,856crs, 60% of Revenue Mix
Slide 17: Highlights – Life Science Services – 9M'FY12
Highlights – Life Science Services- 9M’FY12 Life Science Services Business revenues at Rs. 640crs in 9M’FY12, grew 15% YoY • Constitutes the CMO, DDDS and Healthcare business 1. CMO Services of Sterile Injectibles and Non-sterile products at Rs. 462crs • Grew more than 18%, contributed over 15% to r
Slide 18: Revenue Analysis – Geography wise – 9M'FY12
Revenue Analysis – Geography wise- 9M’FY12 Emerg. China Mkts (Rs crs) 9M'FY 11 9M'FY 12 Mix % 7% 6% YoY % India 30% India 775 929 30% 20% Europe & Japan International 1,768 2,151 70% 22% 19% USA & Canada 934 1,203 39% 29% Europe & Japan 404 575 19% 42% USA & China 253 207 7% -18% Canada Emerging Mar
Slide 19: Operating Expenditure Analysis – 9M'FY12
Operating Expenditure Analysis – 9M’FY12 Expenses YoY 9M ’FY11 % of Sales 9M’FY12 % of Sales (Rs Crs) Growth % Material 1,153 45% 1,309 43% 14% Manufacturing 208 8% 265 9% 27% Staff 535 21% 624 20% 17% SG & A 230 9% 256 8% 11% • Share of Material Costs to sales down due to • Higher value addition in
Slide 20: EBITDA Analysis – 9M'FY12
EBITDA Analysis – 9M’FY12 EBITDA (Rs Crs) 9M'FY 11 9M'FY 12 YoY Growth% Products Business 463 598 29% Services Business 15 95 550% Reported EBITDA 430 643 50% Margins (%) bps variance Products Business 23.3% 24.5% 121 Services Business 2.6% 14.9% 1,225 Consolidated 16.9% 20.9% 396 Reported EBITDA is
Slide 21: Exceptional Items
Exceptional Items Particulars Proforma based on Q3'FY11 Q3'FY12 9M ’FY11 9M’FY12 Feb 3,2012 (Rs Crs) MTM Provs 4 (143) (6) (161) (61) FCMITDA Amortisation 0 (13) (12) (41) (24) Others (6) (8) Total Exceptional Gain/ (Loss) (2) (155) (26) (202) (85) Closing Rates (USD - INR) 44.70 53.10 44.70 53.10 4
Slide 22: Debt Profile
Debt Profile March 31, 2011 September 30, 2011 December 31, 2011 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 190 219 274 Subsidiaries 195 195 184 FCCB 142 0 0 Total 527 414 458 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 438 679 692 Subsidiaries 26 0 0 Rupee Loan Swapped 1,070 91
Slide 23: Outlook
Outlook The overall underlying strength of our business has been strong with increasing order book position and capacity utilisation in all our business segments. The Company expects to continue to build on the robust sustainable revenue and margin growth momentum recorded for the nine month period.
Slide 24: Conference Call Details
Conference Call Details Date : Monday, 06th February, 2012 Time : 4:00 pm IST India Primary Number: +91 22 6629 0301 Secondary Number: +91 22 3065 0122 Local Access Number 6000 1221/ 3940 3977 International USA 1 866 746 2133 UK 0 808 101 1573 Singapore 800 101 2045 Hong Kong 800 964 448 Replay from
Slide 25: For more information
For more information Visit us at www.jubl.com Contact us at nidhi_aggarwal@jubl.com Ph: +91-120 4361002 siddharth@cdr-india.com Ph: +91-22 6645 1209 24 24